港股異動 | 中基長壽科學(0767.HK)暴漲逾28% 長壽ZJ1系列產品於天貓國際上線
格隆匯12月24日丨中基長壽科學(0767.HK)暴漲逾28%,報0.155港元,總市值6億港元。中基長壽科學今早發佈公吿,2021年11月9日,公司全資附屬公司浤烽發展有限公司與淘寶中國控股有限公司簽署天貓國際商户服務協定,於天貓國際網站開設海外旗艦店,銷售ZJ1系列產品營養補充劑,包括ZJ1NMN多系列長壽補充劑、ZJ1VC緩釋片等產品。服務協定的年期為2021年11月9日至2022年12月31日。旗艦店及產品已於2021年12月20日正式上線,為集團增加了一個額外穩定的跨境銷售渠道和收入來源。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.